Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — clinical trials in France
30 open options
- TRIALNARECRUITING
Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease
Malnutrition screening and perioperative nutritional support — 1 site
- TRIALPHASE1RECRUITING
Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease
etanercept and repeated contrast ultrasound — 1 site
- TRIALNARECRUITING
MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
high-resolution diffusion MRI — 1 site
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNANOT_YET_RECRUITING
Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers
Blood ponction — 1 site
- TRIALNARECRUITING
Identification of Diagnosis Biomarkers in the Tears of Alzheimer's Disease Patients: The COG-EYE Pilot Study
Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42) · Collection of a blood sample (5 mL) for blood biomarkers analysis — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
Predictive Factors of Autonomy Loss in Real-life Cohort
no intervention — 5 sites
- TRIALNARECRUITING
Deafness and Cognition in Middle-aged Adults
Cognitive and audiometry evaluation — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALNARECRUITING
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
neuropsychologist interview · questionnaire — 3 sites
- TRIALNARECRUITING
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
Brain MRI · neuropsychological evaluation · Blood — 1 site
- TRIALPHASE4NOT_YET_RECRUITING
Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) — 31 sites
- TRIALPHASE3NOT_YET_RECRUITING
Masitinib in Patients With Mild Alzheimer's Disease
Placebo · Masitinib (4.5) · Standard of care — 9 sites
- TRIALNARECRUITING
Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease
blood sample taken — 2 sites
- TRIALNARECRUITING
Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease
RGn600 · RGn600 Sham — 7 sites
- TRIALNARECRUITING
Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
blood withdrawal — 1 site
- TRIALNARECRUITING
Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)
Thorough Hearing assessment — 4 sites
- TRIALNARECRUITING
Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG
video polysomnography · Attention task — 1 site
- TRIALNARECRUITING
EVASION: Effect of VisuAl Stimulation on attentION
Visual cognitive stimulation exercises · Broadcast of a television program — 1 site
- TRIALNARECRUITING
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
Electroencephalogram (EEG) · Oculomotor tests · MRI — 1 site
- TRIALNANOT_YET_RECRUITING
Physical Exercise to Prevent Mild-cognitive Impairment in Patients With Kidney Disfunctions
Exercise · Control (Standard treatment) — 6 sites
- TRIALPHASE4RECRUITING
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
Daridorexant 50 mg · Placebo · Polysomnography — 1 site
- TRIALNARECRUITING
New Imaging Biomarkers Predictive of MA Progression
MRI follow-up — 1 site
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNARECRUITING
Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease
Control condition · Motor mental imagery · Action execution — 3 sites
- TRIALPHASE3RECRUITING
Effect of CAFfeine on Cognition in Alzheimer's Disease
Caffeine · Placebo — 17 sites
- TRIALNANOT_YET_RECRUITING
Early-phase Telecare Programs for Minor Stroke
Psychoeducation · Computerised Cognitive Stimulation · Usual Care — 3 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.